


**Human TruStain FcX™ (Fc Receptor Blocking Solution)**

**Catalog # / Size:** 2711505 / 50 tests  
2711510 / 200 tests

**Concentration:** NULL




Human TruStain FcX™ treated (blue) or non-treated (red) THP-1 cells stained with an irrelevant mouse IgG1 PE mAb (above). Dotted histogram represents unstained cells.

**Applications:**

**Applications:** Immunohistochemistry

**Recommended Usage:** It is recommended to add 5 microL of Human TruStain FcX™ per million cells in 100 microL staining volume, mix and incubate at room temperature for 5-10 minutes prior to staining with antibody of interest. It is not necessary to wash cells between these blocking and immunostaining steps.

**Application Notes:** This buffer contains specialized human IgG in PBS containing 0.09% sodium azide. It is not recommended to be used for staining human IgG. Handle as biohazard agent.



Human TruStain FcX™ treated (filled histograms) or non-treated (open histograms) THP-1 cells stained with anti-human HLA-DR PE (red) or an isotype control (IgG2a PE, blue) mAbs. Note: non-treated cells show false-negative HLA-DR staining due to high

**Application References:**

1. de la Cruz J, *et al.* 2011. *J. Immunol.* 186:2282. [PubMed](#)
2. Luo L, *et al.* 2011. *Exp Mol Pathol.* 91:596. [PubMed](#)
3. Szerlip NJ, *et al.* 2012. *PNAS.* 109:3041. [PubMed](#)
4. Bromley SK, *et al.* 2013. *J. Immunol.* 190:970. [PubMed](#)
5. Trujillo G, *et al.* 2013. *J. Immunol.* 191:848. [PubMed](#)
6. Edin S, *et al.* 2013. *PLoS One.* 18:74982. [PubMed](#)
7. Euzebio Alves VT, *et al.* 2013. *Infect Immun.* 81:4399. [PubMed](#)
8. Borg ZD, *et al.* 2014. *J. Immunol.* 192:189. [PubMed](#)
9. Klingenberg R, *et al.* 2014. *Eur Heart J.* [PubMed](#)
10. Lines JL, *et al.* 2014. *Cancer Res.* 74:1924. [PubMed](#)
11. Decker D, *et al.* 2014. *Lupus.* 23:802. [PubMed](#)

12. Jitschin R, *et al.* 2014. *Blood*. 123:2663. [PubMed](#)
  13. Anderson ME Jr, *et al.* 2014. *Otolaryngol Head Neck Surg*. 150:880. [PubMed](#)
  14. Giurisato E, *et al.* 2014. *Mol Biol Cell*. 25:1769. [PubMed](#)
  15. Shi J, *et al.* 2014. *Blood*. 123:4015. [PubMed](#)
  16. Kusner LL, *et al.* 2014. *PLoS One*. 9:102231. [PubMed](#)
  17. Fujisawa D, *et al.* 2014. *J Allergy Clin Immunol*. 134:622. [PubMed](#)
  18. Bhardwaj N, *et al.* 2014. *J Virol*. 88:11108. [PubMed](#)
  19. Lieber S, *et al.* 2014. *Mol Pharmacol*. 87:162. [PubMed](#)
  20. Olagnier D, *et al.* 2014. *PLoS Pathog*. 10:1004566. [PubMed](#)
  21. Punyadee N, *et al.* 2015. *J Virol*. 89:1587. [PubMed](#)
  22. Vuong TT, *et al.* 2015. *J Histochem Cytochem*. 63:280. [PubMed](#)
  23. Klingenberg R, *et al.* 2015. *Eur Heart J*. 36:1041. [PubMed](#)
  24. Wilkinson-Ryan I, *et al.* 2015. *PLoS One*.10:125851. [P](#)
- 

**Description:** Human Fc receptors (FcRs) are expressed on a variety of cells, such as monocytes, granulocytes, B cells and dendritic cells. The cells with FcR expression sometimes give false positive or false negative results of immunofluorescent staining due to the FcRs-mediated Ig Fc binding. Human TruStain FcX™ is specially formulated for blocking the FcR-involved unwanted staining without interfering with antibody-mediated specific staining of human cells. Human TruStain FcX™ is compatible with flow cytometric staining with anti-human CD16 (clone 3G8), CD32 (clone FUN-2), and CD64 (clone 10.1) antibodies.